A dverse left ventricular (LV) remodeling after myocardial injury causes tethering of the mitral valve, preventing sufficient coaptation of normal leaflets and resulting in functional mitral regurgitation (MR), 1 which frequently affects patients with myocardial infarction or heart failure (HF). [2] [3] [4] Because secondary functional MR usually develops as a result of LV dysfunction, guideline-directed medical therapy for HF forms the mainstay of therapy. 5 Although β-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) could partially attenuate LV dilation and remodeling after myocardial injury, 6, 7 their effects on LV remodeling were insufficient for reducing the severity of MR, and the morbidity and mortality of patients with functional MR remain high despite standard medical therapy. [8] [9] [10] Moreover, there have been no prospective trials to examine whether medical treatment can reduce functional MR by quantitative assessment of MR. 1, 8, 9 Sacubitril/valsartan, a novel complex of the ARB valsartan with an inhibitor of neprilysin sacubitril, was superior to enalapril in reducing the risks of death and of hospitalization for HF in symptomatic patients with a reduced ejection fraction, 11 and was recently approved as a replacement for ACE inhibitors or ARBs in these patients. 12, 13 Because the neprilysin inhibitor has vasodilating effects and facilitates sodium excretion, 13, 14 combined inhibition of the renin-angiotensin system and neprilysin has greater hemodynamic and neurohormonal effects than an ACE inhibitor or ARB alone. 15, 16 Despite the critical need for newer medical therapies against functional MR, currently there are no effective pharmacological therapies and angiotensin receptor-neprilysin inhibitor (ARNI) might be useful for treating functional MR. The PRIME trial (Pharmacological Reduction of Functional, Ischemic Mitral Regurgitation) was designed to assess the therapeutic impact of ARNI on functional MR. The major hypothesis of this trial was that sacubitril/valsartan would be superior to valsartan alone in improving functional MR via the synergistic effects of dual inhibition of the renin-angiotensin system and neprilysin.
METHODS

Study Design and Oversight
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. We conducted this prospective, multicenter, double-blind, randomized, activecontrolled trial at 4 centers in Korea. The executive committee designed the trial and oversaw the conduct of the trial and data analyses. Novartis, which provided study drug and part of funding, had no role in data collection, data analysis, data interpretation, or writing of the report. The study protocol was approved by the institutional review board at each participating center. All patients provided written informed consent. The first draft of the manuscript was prepared by the first 2 authors, and was reviewed and edited by all the authors. All the authors made the decision to submit the manuscript for publication and vouch for the fidelity of this report to the protocol and for the accuracy and completeness of the data and the analyses.
Study Patients
Eligibility criteria at screening included an age of at least 20 years, stable HF with New York Heart Association (NYHA) class II or III symptoms, an ejection fraction (EF) of 25% to <50% and significant functional MR lasting >6 months, which was assessed by means of transthoracic echocardiography performed by local investigators and was confirmed by an independent core laboratory. Significant functional MR should fulfill all the following 3 criteria: normal mitral valve leaflets and chords, regional or global wall motion abnormalities of LV with tethering of the leaflet, and MR whose effective regurgitant orifice area (EROA) was >0.1 cm 2 , lasting >6 months despite medical treatment with a β-blocker and an ACE inhibitor (or ARB). Patients were required to take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks before screening.
Exclusion criteria at screening included symptomatic hypotension, a systolic blood pressure of <100 mm Hg, an estimated glomerular filtration rate <30 mL/min per 1.73 m 2 , a serum potassium level of >5.0 mmol/L, or a history of angioedema. Patients were also excluded from the trial if they had any evidence of structural mitral valve disease; NYHA IV symptoms; previous valve intervention or cardiac resynchronization therapy; previous hospitalization within 6 weeks; previous history of acute coronary syndrome, stroke, cardiovascular surgery, or percutaneous coronary intervention within 3 months; substantial myocardial ischemia requiring coronary revascularization, an indication for cardiac resynchronization therapy; a plan of coronary revascularization, mitral valve intervention, or heart transplantation during the trial.
Clinical Perspective
What Is New?
• PRIME trial (Pharmacological Reduction of Functional, Ischemic Mitral Regurgitation) has demonstrated that an angiotensin receptor neprilysin inhibitor is more effective in improving functional mitral regurgitation associated with heart failure than an angiotensin receptor blocker.
• In comparison with valsartan, sacubitril/valsartan further reduces the effective regurgitant orifice area, left ventricular end-diastolic volume index, left atrial volume index, and the ratio of mitral inflow velocity to mitral annular relaxation velocity (E/E′).
What Are the Clinical Implications?
• Angiotensin receptor-neprilysin inhibitor may be considered for optimal medical therapy of stable patients with heart failure and functional mitral regurgitation.
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Study Procedures
We randomly assigned patients with significant functional MR in a 1:1 ratio to double-blind treatment with either valsartan or sacubitril/valsartan with the use of a computerized randomization system involving concealed study-group assignments. The randomization was stratified according to ischemic or nonischemic cause of functional MR and cardiac rhythm. The interactive web response system assigned a randomization number to each patient that linked the patient to a treatment group and specified a unique medication number for study drug to be dispensed. Study medications were identical in appearance. After randomization, patients were switched from the ACE inhibitor or ARB that they had been receiving to the study drug, which was administered 36 hours after the last dose of ACE inhibitors to minimize the risk of angioedema caused by concomitant inhibition of ACE and neprilysin. Patients were started on valsartan 40 to 80 mg twice daily or sacubitril/valsartan 24/26 to 49/51 mg twice daily and titrated as tolerated at 4-week intervals to a maximum dose of valsartan 160 mg or sacubitril/valsartan 97/103 mg twice daily. All other drug treatment including β-blockers and diuretics were continued. Patients were treated for 12 months and evaluated every 4 weeks during the first 2 to 3 months of therapy and every 2 to 6 months thereafter. Study investigators, responsible pharmacists, and patients were masked to treatment allocation for the duration of the trial. Echocardiographic evaluation was performed at randomization and at the 12-month follow-up or early termination visits. Experienced sonographers, who were dedicated to this trial, performed a standard 2-dimensional and Doppler echocardiographic examination on all patients using an iE33 echocardiography system (Philips). Echocardiographic studies were stored digitally in Digital Imaging and Communications in Medicine format and transferred to the echocardiography core laboratory, where measurements were performed using offline digital review workstation by an investigator (Dr Kang) who was masked to the patient data, treatment allocation, study sequence, and previous measures in each patient. The end-systolic volume, end-diastolic volume, and LV ejection fraction (LVEF) were calculated with the biplane Simpson method. 17 Because the input impedance of systemic circulation providing a precise measurement of the LV afterload is not feasible in practice, arterial impedance was approximated by the systolic arterial pressure to stroke volume index ratio. 18 EROA was determined by dividing the regurgitant flow rate, calculated as 2πr 2 × aliasing velocity, where r is the proximal isovelocity surface area (PISA) radius, by peak MR velocity. 19 The radius of PISA was measured at early, mid, and late systole from a frame with the most satisfactory hemispheric PISA and averaged ( Figure I in the online-only Data Supplement). A significant change in the severity of MR is prespecified as the absolute value of change in EROA >0.1 cm 2 or the percentage change in EROA to baseline EROA >50%. A regurgitant volume was estimated as EROA multiplied by the velocity time integral of the MR jet.
End Points
The primary end point was change in EROA of functional MR from baseline to 12 months follow-up. Secondary end points included changes in regurgitant volume, end-systolic volume, end-diastolic volume, and incomplete mitral leaflet closure area.
Statistical Analysis
We assumed a baseline mean EROA of 0.26 cm 2 , a common SD of 0.09 cm 2 , 20 and a dropout rate of 10%. Given these assumptions, we calculated that a sample size of 114 patients randomly assigned to 2 groups would provide 80% power to detect a difference of 0.05 cm 2 in the EROA between groups, using a 2-sided t test with an α-level of 0.05. The primary analysis was prespecified as measurement of a change between baseline and 12-month follow-up or the last assessment, and included all randomly assigned patients who had a baseline and at least one follow-up assessment, according to the intention-to-treat principle. The secondary analysis was performed with the use of 12-month follow-up assessment from completers only. Baseline clinical and echocardiographic characteristics were compared in the 2 treatment groups with the use of the Student t test or the Mann-Whitney U test for continuous variables and the χ 2 test or Fisher exact test for categorical variables as appropriate. The null hypothesis was that there would be no betweengroup difference regarding the change in EROA from baseline to 12-month follow-up. This hypothesis was tested in an intention-to-treat analysis. For the primary and secondary end points, we used 2 statistical methods. First, we used the t test methods for differences between groups as described in the protocol. Second, to obtain a correct P value and CI, we analyzed the outcome variables using the linear mixedeffects models that accounted for clustering effects of stratified randomization. The models were fitted by using the groups as the fixed effect, the stratification as the random effect, and the responses as the change in the variables from baseline to 12-month follow-up. Because there was a significant difference in age between groups, age-adjusted analysis was also performed in the second method. Because these analytic results are similar, we reported only the results of the linear mixed-effects models. In addition, we performed tests of homogeneity of the stratification-specific effects for the outcomes using a linear regression model to test for interaction between the treatment and strata where the strata were treated with a fixed effect. Estimated between-group differences are presented with 95% CI. We used the Fisher exact test to compare between-group differences in significant changes of MR. The prespecified subgroups defined at baseline were ischemic versus nonischemic cause of functional MR, and sinus rhythm versus atrial fibrillation. The consistency of treatment effect was assessed among prespecified subgroups with tests for interaction. All reported P values were 2 sided, and a P value <0.05 was considered statistically significant. SAS software, version 9.1 (SAS Institute, Inc) and R package, version 3.3.1, were used for statistical analyses.
RESULTS
Patient Characteristics
Between March 2016 and January 2017, we enrolled a total of 118 patients; 60 patients were randomly assigned to sacubitril/valsartan and 58 to valsartan. The numbers of patients who were screened, randomly assigned to a treatment group, and included in the primary analysis are shown in Figure 1 . The mean age of the patients was 62.6±11.2 years and 61% were men. Cause of functional MR was ischemic in 42 (36%) patients and nonischemic in 76 (64%), whereas atrial fibrillation was present in 31 (26%) patients. Mean LVEF was 34±7%, mean effective regurgitant orifice area of MR 0.20±0.10 cm 2 , and mean regurgitant volume 35±16 mL. The treatment groups were generally well balanced with regard to baseline clinical and echocardiographic characteristics, with the exception of their age (Table 1 ). All patients had been taking either an ACE inhibitor or ARB and 88% were on diuretics before enrollment.
Follow-Up
No patients were lost to follow-up and there was no emergency requiring unblinding. Except for one patient who died suddenly, follow-up echocardiographic examination was performed at 362±8 days for 104 (89%) patients who completed the study (completers) or at 171±98 days after randomization for 13 (11%) who subsequently withdrew from therapy. Primary analysis included all 117 (99%) patients with follow-up echocardiographic assessment done (Figure 1 ). Among Of the 247 patients who had received a diagnosis of heart failure with reduced EF and significant functional MR at least 6 months before enrollment, 80 had mild MR or mitral valve prolapse and 36 had left ventricular ejection fraction >50% or <25% on echocardiography performed for screening; 131 patients were assessed for eligibility, 13 of whom were excluded. Of the 118 patients who underwent randomization, 60 were assigned to the sacubitril/valsartan group and 58 to the valsartan group; with the exception of 1 patient who died suddenly, all these patients were included in the intention-to-treat analysis. EF indicates ejection fraction; eGFR, estimated glomerular filtration rate; and MR, mitral regurgitation.
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the 104 completers, target dose was achieved in 31 (61%) patients in the sacubitril/valsartan group and in 37 (70%) in the valsartan group, and the mean doses in the sacubitril/valsartan and valsartan groups were 77±30% and 82±29% of target dose, respectively. The use of concomitant HF medications was similar, but significantly higher percentages of target ARB dose were reached during follow-up in both groups (Table 2) .
End Points
In an intention-to-treat analysis including 117 (99%) patients, EROA was changed from 0.195±0.094 to 0.137±0.089 cm 2 in the sacubitril/valsartan group and from 0.210±0.107 to 0.192±0.161 cm 2 in the valsartan group (Table 3) . EROA was decreased by 30% and 9% in the sacubitril/valsartan group and the valsartan group, respectively. The primary end point of change in EROA (Figure 2 ) was significantly different between the sacubitril/valsartan group and the valsartan group (-0.058±0.095 versus -0.018±0.105 cm 2 ; P=0.032).
In the prespecified subgroup analysis, we identified no interaction with the cause of functional MR or with cardiac rhythm (P=0.54; Table I in the online-only Data Supplement). The secondary analysis of change in EROA in the completers only yielded similar results (-0.077±0.080 versus -0.030±0.096; P=0.008) with a greater reduction in the sacubitril/valsartan group (Table 4). EROA was decreased by 39% and 14% in the sacubitril/valsartan group and the valsartan group, respectively. At 12 months, 64 (62%) of 104 completers had no significant change in MR, whereas 21 in the sacubitril/valsartan group and 14 in the valsartan group showed a significant decrease in MR, and a significant increase in MR occurred in 5 patients in the valsartan group only; the between-group difference in significant changes of MR was significant (P=0.037; Figure 3 ). Plus-minus values are means±SD. The baseline characteristics did not differ significantly between the 2 treatment groups, with the exception of age (P=0.040).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; EROA, effective regurgitant orifice area; ILCA, incomplete leaflet closure area; MR, mitral regurgitation; and NYHA, New York Heart Association. Regurgitant volume was changed from 34.7±14.7 to 23.1±13.3 mL in the sacubitril/valsartan group and from 35.9±17.4 to 31.6±23.7 mL in the valsartan group (Table 3), and the percent decrease was 33% and 12% in the sacubitril/valsartan group and the valsartan group, respectively. The secondary end point, decrease in regurgitant volume, was also significantly greater in the sacubitril/valsartan group than in the valsartan group (mean difference of change, -7.3 mL; 95% CI, -12.6 to -1.9; P=0.009). The secondary analysis in completers revealed similar results (mean difference of change, -8.3 mL; 95% CI, -13.6 to -2.9; P=0.003), and no significant interaction with cause of functional MR or with cardiac rhythm was identified (P=0.42).
At follow-up, end-systolic and end-diastolic volumes of LV were significantly smaller in the sacubitril/ valsartan group, and decrease in end-diastolic volume index alone was significantly greater in the sacubitril/ valsartan group than in the valsartan group (mean difference of change, -7.0 mL/m 2 ; 95% CI, -13.8 to -0.2; P=0.044). Mean reduction in end-systolic volume and end-diastolic volume were 15.6 (12.4%) and 19.6 (10.3%) mL in the sacubitril/valsartan group and 9.9 (6.8%) and 9.0 (4.2%) mL in the valsartan were no significant differences in the changes of LV end-systolic volume, LV end-diastolic volume, and incomplete mitral leaflet closure area between the treatment groups.
Other Follow-Up Changes in Completers
At follow-up, blood pressure was reduced by 7.1±15.8/6.2±12.7 mm Hg in the sacubitril/valsartan group and 3.3±16.0/2.7±12.6 mm Hg in the valsartan group, and the differences in the changes of blood pressures were not significant (Table 5 ). After 12 months of treatment, early mitral inflow (E) velocity and the ratio of mitral inflow velocity to mitral annular relaxation velocity (E/E′) were significantly lower in the sacubitril/valsartan group than in the valsartan group. The decrease in E/E′ was significantly greater in the sacubitril/valsartan group than in the valsartan group (mean difference of change, -2.7; 95% CI, -5.1 to -0.2; P=0.037). The decrease in left atrial volume index (mean difference of change, -8.9 mL/m 2 ; 95% CI, -14.6 to -3.3; P=0.002) and the decrease in arterial impedance (mean difference of change, -1.82 mm Hg/mL per m 2 ; 95% CI, -3.37 to -0.26; P=0.023) were also significantly greater in the sacubitril/valsartan group. Among 104 completers, 58 (56%) remained in the same NYHA class, whereas 23 (45%) in the sacubitril/valsartan group and 23 (43%) in the valsartan group improved by 1 or 2 NYHA classes with no significant difference between treatment groups (P=0.86). NYHA class improvement was noted in 27 (77%) of 35 patients with a significant decrease in MR, but only in 19 (28%) of 69 patients without a significant decrease (P<0.001).
Adverse Events
During follow-up, 7 patients (12%) had serious adverse events, including 1 sudden death in the sacubitril/valsartan group; in the valsartan group, 9 (16%) had serious adverse events (Table 6) . No patient underwent cardiac surgery or cardiac resynchronization therapy during the trial period, whereas one patient underwent an elective percutaneous coronary intervention. The number of patients with symptomatic hypotension, angioedema, a serum creatinine level of ≥2.5 mg/dL, and hyperkalemia did not differ between the treatment groups.
DISCUSSION
In this double-blind, randomized trial, we found that the ARNI sacubitril/valsartan was more effective in EDVI indicates end-diastolic volume index; EROA, effective regurgitant orifice area; ESVI, end-systolic volume index; ILCA, incomplete leaflet closure area; and MR mitral regurgitation.
*P values were calculated by using the linear mixed-effect model. 
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improving functional MR associated with HF than the ARB valsartan. A strong association between functional MR severity and both all-cause mortality and HF hospitalization has been reported. 4, 9, 10, 21 However, the benefits of a surgical or percutaneous intervention should be balanced against the risks associated with the procedure, and there is remarkably little evidence that correcting severe functional MR by an intervention prolongs life or even improves symptoms for a prolonged period. 5 Although mitral valve surgery is the standard of care for primary severe MR, outcomes of mitral valve interventions for secondary severe MR remain suboptimal, and these options may be considered only in carefully selected patients with severe symptoms unresponsive to optimal medical therapy. 5, 9, [22] [23] [24] Although guideline-directed medical therapy for HF is first-line treatment for patients with secondary functional MR, this strategy is usually insufficient, because ACE inhibitors, ARBs, and β-blockers fail to reverse adverse LV remodeling and functional MR. [6] [7] [8] 23, 25 In the PARADIGM-HF trial (Prospective Comparison of ARNI With ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan significantly reduced morbidity and mortality in comparison with enalapril, 11 and replacement of an ACE inhibitor or ARB by an ARNI is recommended in symptomatic patients with HF and a reduced EF. 12 In most ARNI trials, including the PARADIGM-HF trial, the effect of ARNI on cardiac structure and function was not evaluated, 13 and only the PARAMOUNT trial (Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction) included echocardiographic end points. Left atrial size was significantly decreased in the sacubitril/valsartan group in comparison with the valsartan group, but there were no significant differences in other echocardiographic end points in the trial. 16 We presently demonstrated that, in comparison with valsartan, sacubitril/valsartan has a more favorable effect on MR, which may mediate in part the BP indicates blood pressure; E, early mitral inflow velocity; E′, mitral relaxation velocity; and E/E′, mitral inflow to mitral relaxation velocity ratio. *P values were calculated by using the linear mixed-effect model. substantial clinical benefits observed in the PARADIGM-HF trial, although this trial did not report the number of patients with functional MR at baseline. 11 Because medical treatment with sacubitril/valsartan achieved significant decrease in functional MR without increasing the incidence of serious adverse events, we suggest that an ARNI should be also considered in medical therapy for patients who have HF with functional MR.
Although the absolute difference in EROA between the treatment groups may seem small, EROA was decreased by 30% in the sacubitril/valsartan group in comparison with the 9% reduction in the valsartan group; the percentage decrease of regurgitant volume was 33% and 12% in the sacubitril/valsartan and the valsartan group, respectively. Such differences in EROA and regurgitant volume could lead to significant differences in the changes of left atrial volume index and E/E′, an echocardiographic marker of left atrial and LV end-diastolic pressures. The LV volumes at 12 months were significantly smaller and the changes in LV volumes (significant difference in LV end-diastolic volume index only) also tended to be larger in the sacubitril/valsartan group, but EF at 12 months and changes in EF were similar between the treatment groups. Insufficient increase in mitral leaflet area in response to LV remodeling is associated with the development of chronic functional MR, 26 and even small decreases in LV volumes might restore the leaflet adaptation to the geometric demands imposed by LV remodeling, and reduce functional MR in the sacubitril/valsartan group. In addition, a significantly greater reduction in arterial impedance (afterload) might contribute to a reduction of functional MR in the sacubitril/valsartan group. Further studies with hemodynamic and biomarker monitoring or 3-dimensional echocardiography are necessary to evaluate the way in which ARNI works for reduction of MR. Functional MR is common and often silent in patients with HF or myocardial infarction, 3, 27 and echocardiography is very useful for the evaluation of MR in these patients. 1, 23 Because qualitative grading of MR is prone to error, quantitative assessment with PISA has become the standard approach to establish the severity of MR and provides measures of EROA and regurgitant volume. 1, 19 Several small studies have examined the effect of medical therapies on functional MR, but such previous studies 9, [28] [29] [30] were nonrandomized, open-labeled, or used qualitative grading of MR. Our trial involved quantitative assessment of MR, which facilitated an objective examination of our hypothesis and detection of significant differences in the change of EROA between the treatment groups even with a small sample size.
Study Limitations
The degree of MR is best defined by the EROA. However, the PISA radius may change during systole, and EROA varies with loading conditions and is often underestimated because of noncircular orifice geometry in functional MR. 1, 9 To overcome such inherent weaknesses related to echocardiographic quantitation of functional MR, we averaged the radius of PISA through systole and measured EROA under the same stable conditions and at the same settings in each patient.
Because ACE inhibitors and ARBs showed similar effects on LV remodeling, 7 we assumed similar effects on functional MR between ACE inhibitors and ARBs. Although ACE inhibitors remain the preferred choice for treatment of HF, valsartan was chosen as active control to assess the effect of sacubitril clearly.
Our trial showed a significant between-group difference in reversal of LV end-diastolic volume index only, although a recent observational study reported significant decreases in both MR severity and LV volumes after switching to sacubitril/valsartan. 31 Echocardiography is a standard imaging method for the evaluation of MR, 32 but it is not as accurate as cardiac MRI for measurement of LV volumes. Our choice of echocardiography as the primary imaging tool could be the limitation for assessment of LV remodeling. Otherwise, MR reduction for <1 year might be insufficient to demonstrate the significant difference of LV volume changes in this small study. Further larger studies with different imaging tools are needed to evaluate the effects of ARNI on LV remodeling. 
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Because the loading conditions in MR allow ejection into a lower-impedance left atrium, LVEF overestimates systolic function of the LV in MR, and a higher cutoff for normal LVEF >60% is used in MR than EF >50% used in other types of heart disease. 5 Because of these favorable loading conditions in MR, we included patients with LVEF up to 50%, although sacubitril/valsartan is approved for HF with reduced EF (LVEF <35%-40%). 12 Because the reversibility of LV remodeling and functional MR may be smaller when LV dilation is extreme and advanced HF is established, 33 we excluded patients with an LVEF <25%. The results of our study may not be applicable to patients who have functional MR associated with extreme LV dilation or LVEF <25%.
It should be also pointed out that our trial is a mechanistic study, not an outcome trial. Thus, our results do not suggest that an ACE inhibitor or ARB should be replaced with an ARNI in guideline-directed medical therapy for patients with functional MR.
Conclusion
Among patients with secondary functional MR, sacubitril/valsartan reduced MR to a greater extent than did valsartan. ARNI may be considered for optimal medical therapy of patients with HF and functional MR.
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